tiprankstipranks
Sino Biopharmaceutical Ltd (DE:SMZ1)
FRANKFURT:SMZ1
Germany Market
SMZ1
Sino Biopharmaceutical
RESEARCH TOOLSreports
Want to see DE:SMZ1 full AI Analyst Report?

Sino Biopharmaceutical (SMZ1) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

SMZ1 Analyst Ratings

Strong Buy
11Ratings
Strong Buy
10 Buy
1 Hold
0 Sell
Based on 11 analysts giving stock ratings to
Sino
Biopharmaceutical
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

SMZ1 Stock 12 Month Forecast

Average Price Target

€0.92
▲(39.91% Upside)
Based on 11 Wall Street analysts offering 12 month price targets for Sino Biopharmaceutical in the last 3 months. The average price target is €0.92 with a high forecast of €1.19 and a low forecast of €0.76. The average price target represents a 39.91% change from the last price of €0.66.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","-1":"-€1","-0.25":"-€0.25","0.5":"€0.5","1.25":"€1.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1.1903696456916,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€1.19</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.923404836,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€0.92</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.7575079563492,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€0.76</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.25,0.5,1.25,2],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.684,0.7229515112070461,0.7619030224140924,0.8008545336211385,0.8398060448281847,0.8787575560352308,0.917709067242277,0.9566605784493231,0.9956120896563692,1.0345636008634154,1.0735151120704616,1.1124666232775078,1.1514181344845538,{"y":1.1903696456916,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.684,0.7024157566153847,0.7208315132307693,0.7392472698461539,0.7576630264615385,0.7760787830769231,0.7944945396923078,0.8129102963076924,0.8313260529230769,0.8497418095384616,0.8681575661538462,0.8865733227692307,0.9049890793846154,{"y":0.923404836,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.684,0.6896544581807077,0.6953089163614155,0.7009633745421231,0.7066178327228309,0.7122722909035385,0.7179267490842461,0.7235812072649539,0.7292356654456615,0.7348901236263692,0.7405445818070769,0.7461990399877846,0.7518534981684923,{"y":0.7575079563492,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.448,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.429,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.473,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.554,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.799,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.951,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.872,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.77,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.749,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.679,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.669,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.65,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.684,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€1.19Average Price Target€0.92Lowest Price Target€0.76
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BOCOM International Holdings Company Analyst forecast on DE:SMZ1
Unknown Analyst
BOCOM International Holdings Company
Not Ranked
BOCOM International Holdings Company
€0.92→€0.83
Buy
26.33%
Upside
Reiterated
03/30/26
BOCOM International Holdings Company Sticks to Its Buy Rating for Sino Biopharmaceutical (SBMFF)
Citic Securities Analyst forecast on DE:SMZ1
Unknown Analyst
Citic Securities
Not Ranked
Citic Securities
€0.97
Buy
47.66%
Upside
Reiterated
03/30/26
Citic Securities Keeps Their Buy Rating on Sino Biopharmaceutical (SBMFF)
CMB International Securities Analyst forecast on DE:SMZ1
Jill Wu
CMB International Securities
CMB International Securities
€0.94
Buy
42.74%
Upside
Reiterated
03/30/26
CMB International Securities Sticks to Their Buy Rating for Sino Biopharmaceutical (SBMFF)
Jefferies Analyst forecast on DE:SMZ1
Chu Wang
Jefferies
Jefferies
€0.76
Buy
14.85%
Upside
Reiterated
03/30/26
Jefferies Reaffirms Their Buy Rating on Sino Biopharmaceutical (SBMFF)
Bank of China Analyst forecast on DE:SMZ1
Unknown Analyst
Bank of China
Not Ranked
Bank of China
€0.87
Buy
31.26%
Upside
Reiterated
03/27/26
Sino Biopharmaceutical (SBMFF) Gets a Buy from Bank of China
Citi Analyst forecast on DE:SMZ1
Unknown Analyst
Citi
Not Ranked
Citi
€1.08
Buy
64.07%
Upside
Reiterated
03/27/26
Sino Biopharmaceutical (SBMFF) Gets a Buy from Citi
Bank of America Securities Analyst forecast on DE:SMZ1
Unknown Analyst
Bank of America Securities
Not Ranked
Bank of America Securities
€0.8
Buy
21.41%
Upside
Reiterated
03/27/26
Bank of America Securities Sticks to Their Buy Rating for Sino Biopharmaceutical (SBMFF)
CICC Analyst forecast on DE:SMZ1
Unknown Analyst
CICC
Not Ranked
CICC
€0.96
Buy
46.02%
Upside
Reiterated
03/27/26
CICC Keeps Their Buy Rating on Sino Biopharmaceutical (SBMFF)
UBS Analyst forecast on DE:SMZ1
Anita Wei
UBS
UBS
€1.19
Buy
80.48%
Upside
Reiterated
03/27/26
Analysts Offer Insights on Healthcare Companies: Annexon Biosciences (NASDAQ: ANNX), Innovent Biologics (Other OTC: IVBXF) and Sino Biopharmaceutical (Other OTC: SBMFF)
Nomura Analyst forecast on DE:SMZ1
Unknown Analyst
Nomura
Not Ranked
Nomura
€0.94
Buy
42.25%
Upside
Reiterated
03/26/26
Nomura Keeps Their Buy Rating on Sino Biopharmaceutical (SBMFF)
Bernstein Analyst forecast on DE:SMZ1
Rebecca Liang
Bernstein
Bernstein
€0.86
Hold
29.62%
Upside
Reiterated
02/09/26
Bernstein Remains a Hold on Sino Biopharmaceutical (SBMFF)
Daiwa Analyst forecast on DE:SMZ1
Unknown Analyst
Daiwa
Not Ranked
Daiwa
€1.08
Buy
64.07%
Upside
Reiterated
11/12/25
GF Securities Analyst forecast on DE:SMZ1
Unknown Analyst
GF Securities
Not Ranked
GF Securities
€1.25
Buy
89.34%
Upside
Reiterated
10/14/25
HSBC Analyst forecast on DE:SMZ1
Linda Shu
HSBC
HSBC
€1.04
Buy
57.51%
Upside
Reiterated
09/30/25
Guotai Haitong Analyst forecast on DE:SMZ1
Unknown Analyst
Guotai Haitong
Not Ranked
Guotai Haitong
€1.08
Buy
64.07%
Upside
Reiterated
09/29/25
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BOCOM International Holdings Company Analyst forecast on DE:SMZ1
Unknown Analyst
BOCOM International Holdings Company
Not Ranked
BOCOM International Holdings Company
€0.92→€0.83
Buy
26.33%
Upside
Reiterated
03/30/26
BOCOM International Holdings Company Sticks to Its Buy Rating for Sino Biopharmaceutical (SBMFF)
Citic Securities Analyst forecast on DE:SMZ1
Unknown Analyst
Citic Securities
Not Ranked
Citic Securities
€0.97
Buy
47.66%
Upside
Reiterated
03/30/26
Citic Securities Keeps Their Buy Rating on Sino Biopharmaceutical (SBMFF)
CMB International Securities Analyst forecast on DE:SMZ1
Jill Wu
CMB International Securities
CMB International Securities
€0.94
Buy
42.74%
Upside
Reiterated
03/30/26
CMB International Securities Sticks to Their Buy Rating for Sino Biopharmaceutical (SBMFF)
Jefferies Analyst forecast on DE:SMZ1
Chu Wang
Jefferies
Jefferies
€0.76
Buy
14.85%
Upside
Reiterated
03/30/26
Jefferies Reaffirms Their Buy Rating on Sino Biopharmaceutical (SBMFF)
Bank of China Analyst forecast on DE:SMZ1
Unknown Analyst
Bank of China
Not Ranked
Bank of China
€0.87
Buy
31.26%
Upside
Reiterated
03/27/26
Sino Biopharmaceutical (SBMFF) Gets a Buy from Bank of China
Citi Analyst forecast on DE:SMZ1
Unknown Analyst
Citi
Not Ranked
Citi
€1.08
Buy
64.07%
Upside
Reiterated
03/27/26
Sino Biopharmaceutical (SBMFF) Gets a Buy from Citi
Bank of America Securities Analyst forecast on DE:SMZ1
Unknown Analyst
Bank of America Securities
Not Ranked
Bank of America Securities
€0.8
Buy
21.41%
Upside
Reiterated
03/27/26
Bank of America Securities Sticks to Their Buy Rating for Sino Biopharmaceutical (SBMFF)
CICC Analyst forecast on DE:SMZ1
Unknown Analyst
CICC
Not Ranked
CICC
€0.96
Buy
46.02%
Upside
Reiterated
03/27/26
CICC Keeps Their Buy Rating on Sino Biopharmaceutical (SBMFF)
UBS Analyst forecast on DE:SMZ1
Anita Wei
UBS
UBS
€1.19
Buy
80.48%
Upside
Reiterated
03/27/26
Analysts Offer Insights on Healthcare Companies: Annexon Biosciences (NASDAQ: ANNX), Innovent Biologics (Other OTC: IVBXF) and Sino Biopharmaceutical (Other OTC: SBMFF)
Nomura Analyst forecast on DE:SMZ1
Unknown Analyst
Nomura
Not Ranked
Nomura
€0.94
Buy
42.25%
Upside
Reiterated
03/26/26
Nomura Keeps Their Buy Rating on Sino Biopharmaceutical (SBMFF)
Bernstein Analyst forecast on DE:SMZ1
Rebecca Liang
Bernstein
Bernstein
€0.86
Hold
29.62%
Upside
Reiterated
02/09/26
Bernstein Remains a Hold on Sino Biopharmaceutical (SBMFF)
Daiwa Analyst forecast on DE:SMZ1
Unknown Analyst
Daiwa
Not Ranked
Daiwa
€1.08
Buy
64.07%
Upside
Reiterated
11/12/25
GF Securities Analyst forecast on DE:SMZ1
Unknown Analyst
GF Securities
Not Ranked
GF Securities
€1.25
Buy
89.34%
Upside
Reiterated
10/14/25
HSBC Analyst forecast on DE:SMZ1
Linda Shu
HSBC
HSBC
€1.04
Buy
57.51%
Upside
Reiterated
09/30/25
Guotai Haitong Analyst forecast on DE:SMZ1
Unknown Analyst
Guotai Haitong
Not Ranked
Guotai Haitong
€1.08
Buy
64.07%
Upside
Reiterated
09/29/25
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Sino Biopharmaceutical

3 Months
xxx
Success Rate
3/5 ratings generated profit
60%
Average Return
+11.10%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +11.10% per trade.
1 Year
Linda ShuHSBC
Success Rate
3/5 ratings generated profit
60%
Average Return
+6.42%
Copying Linda Shu's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +6.42% per trade.
2 Years
xxx
Success Rate
3/5 ratings generated profit
60%
Average Return
+60.92%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 60.00% of your transactions generating a profit, with an average return of +60.92% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SMZ1 Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
1
0
0
6
6
Buy
2
3
2
6
4
Hold
0
0
1
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
3
3
3
13
11
In the current month, SMZ1 has received 10 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. SMZ1 average Analyst price target in the past 3 months is 0.92.
Each month's total comprises the sum of three months' worth of ratings.

SMZ1 Financial Forecast

SMZ1 Earnings Forecast

Next quarter’s earnings estimate for SMZ1 is €0.02 with a range of €0.02 to €0.02. The previous quarter’s EPS was <€0.01. SMZ1 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year SMZ1 has Performed in-line its overall industry.
Next quarter’s earnings estimate for SMZ1 is €0.02 with a range of €0.02 to €0.02. The previous quarter’s EPS was <€0.01. SMZ1 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year SMZ1 has Performed in-line its overall industry.

SMZ1 Sales Forecast

Next quarter’s sales forecast for SMZ1 is €2.53B with a range of €2.53B to €2.53B. The previous quarter’s sales results were €1.73B. SMZ1 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year SMZ1 has Performed in-line its overall industry.
Next quarter’s sales forecast for SMZ1 is €2.53B with a range of €2.53B to €2.53B. The previous quarter’s sales results were €1.73B. SMZ1 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year SMZ1 has Performed in-line its overall industry.

SMZ1 Stock Forecast FAQ

What is DE:SMZ1’s average 12-month price target, according to analysts?
Based on analyst ratings, Sino Biopharmaceutical Ltd’s 12-month average price target is 0.92.
    What is DE:SMZ1’s upside potential, based on the analysts’ average price target?
    Sino Biopharmaceutical Ltd has 39.91% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Sino Biopharmaceutical Ltd a Buy, Sell or Hold?
          Sino Biopharmaceutical Ltd has a consensus rating of Strong Buy, which is based on 10 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Sino Biopharmaceutical Ltd’s share price target?
            The average share price target for Sino Biopharmaceutical Ltd is 0.92. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €1.19 ,and the lowest forecast is €0.76. The average share price target represents 39.91% Increase from the current price of €0.66.
              What do analysts say about Sino Biopharmaceutical Ltd?
              Sino Biopharmaceutical Ltd’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.
                How can I buy shares of Sino Biopharmaceutical Ltd?
                To buy shares of DE:SMZ1, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.